NCT01350401View on ClinicalTrials.gov

Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

June 1, 2011

Primary Completion Date

February 17, 2016

Study Completion Date

March 1, 2018

Conditions
Melanoma
Interventions
GENETIC

Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T

Cytoreductive chemotherapy followed by infusion of NY-ESO-1ᶜ²⁵⁹T

Trial Locations (2)

63110

Washington University in St. Louis, St Louis

06520

Yale School of Medicine, New Haven

Sponsors

Lead Sponsor

Adaptimmune
All Listed Sponsors
lead

Adaptimmune

INDUSTRY

NCT01350401 - Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma | Biotech Hunter | Biotech Hunter